Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products

Executive Summary

Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies

You may also be interested in...



Amgen To Study Aranesp Anemia Indication In Heart Failure Patients

Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure

Amgen To Study Aranesp Anemia Indication In Heart Failure Patients

Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure

Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway

Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel